HIGH-DOSE CYTARABINE ALONE VERSUS CYTARABINE PLUS ANTHRACYCLINE FOR CONSOLIDATION THERAPY IN NONPROMYELOCYTIC ACUTE MYELOID LEUKEMIA

  • So Yeon Kim Department of Hematology-Oncology, Dong-A University School of Medicine, Busan, Republic of Korea
  • Seok Jae Huh Department of Hematology-Oncology, Dong-A University School of Medicine, Busan, Republic of Korea
  • Ji Hyun Lee Department of Hematology-Oncology, Dong-A University School of Medicine, Busan, Republic of Korea
  • Suee Lee Department of Hematology-Oncology, Dong-A University School of Medicine, Busan, Republic of Korea
  • Sung Yong Oh Department of Hematology-Oncology, Dong-A University School of Medicine, Busan, Republic of Korea
  • Hyo-Jin Kim Department of Hematology-Oncology, Dong-A University School of Medicine, Busan, Republic of Korea
  • Dae Sik Kim Department of Hematology-Oncology, Korea University School of Medicine, Seoul, Republic of Korea
  • Ka-Won Kang Department of Hematology-Oncology, Korea University School of Medicine, Seoul, Republic of Korea
  • Se Ryeon Lee Department of Hematology-Oncology, Korea University School of Medicine, Seoul, Republic of Korea
  • Yong Park Department of Hematology-Oncology, Korea University School of Medicine, Seoul, Republic of Korea
  • Hwa Jung Sung Department of Hematology-Oncology, Korea University School of Medicine, Seoul, Republic of Korea
  • Chul Won Choi Department of Hematology-Oncology, Korea University School of Medicine, Seoul, Republic of Korea
  • Byung Soo Kim 2Department of Hematology-Oncology, Korea University School of Medicine, Seoul, Republic of Korea
  • Sung-Hyun Kim Division of Hematology-Oncology, Dong-A University Hospital, Daeshin Park Road 26, Seo-gu, Busan, 602-715, South Korea

Abstract

Background: Standard consolidation therapy of acute myeloid leukemia (AML) contains highdose cytarabine (HiDC). However, optimal dose of cytarabine and benefit of additional chemotherapeutic agents remain unresolved problems.
Methods: 142 patients among 173 newly diagnosed AML patients, who achieved complete remission following induction chemotherapy in 4 independent institutes were retrospectively analyzed. Patients were divided into 3 groups by consolidation regimens: HiDC alone (Group A), HiDC plus anthracycline (Group B), and intermediate-dose cytarabine plus anthracycline (Group C).
Results: Overall survival (OS), relapse-free survival (RFS), disease-free survival (DFS), and event-free survival (EFS) were not significantly different in Group A vs. Group B. However, Group B showed longer RFS, DFS, and EFS, as compared with Group C. In this study, the addition of anthracycline to HiDC did not survival, and had more toxicity. HiDC enhanced RFS, DFS, and EFS as compared with intermediate-dose cytarabine.
Conclusions: Therefore, HiDC single therapy could be considered as standard consolidation therapy for AML.

Published
Apr 3, 2018
How to Cite
KIM, So Yeon et al. HIGH-DOSE CYTARABINE ALONE VERSUS CYTARABINE PLUS ANTHRACYCLINE FOR CONSOLIDATION THERAPY IN NONPROMYELOCYTIC ACUTE MYELOID LEUKEMIA. International Journal of Drug Research and Technology, [S.l.], v. 8, n. 1, apr. 2018. ISSN 2277-1506. Available at: <http://ijdrt.com/index.php/drug-research-and-technology/article/view/high-dose-cytarabine-alone-versus-cytarabine-plus-anthracycline-for-consolidation-therapy-in-nonpromyelocytic-acute-myeloid-leukemia>. Date accessed: 24 apr. 2018.
Section
Research Article